Metabolon's $60M Credit Facility: Fueling Growth and Innovation in Metabolomics
May 17, 2024, 4:25 pm
Location: Canada, Newfoundland and Labrador, Morrisville
Employees: 201-500
Founded date: 2000
Total raised: $220.1M
Metabolon, a renowned company based in Morrisville, NC, specializing in providing metabolomics solutions for life science research, diagnostic, therapeutic development, and precision medicine applications, recently secured a substantial $60M credit facility. This financial boost, provided by Trinity Capital, is set to propel Metabolon's growth initiatives, expand its research and development efforts, and support its global expansion plans, including market penetration initiatives and strategic partnerships.
Led by CEO Rohan (Ro) Hastie, Metabolon stands as a global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research. With over 20 years of experience, 10,000+ projects, 3,000+ publications, and certifications such as ISO 9001:2015, CLIA, and CAP, Metabolon has established itself as a pioneer in the field. The company's Global Discovery Panel, fueled by a vast proprietary metabolomics reference library, offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, to support customer needs from discovery through clinical trials and product life-cycle management.
In a statement regarding the news, CEO Rohan (Ro) Hastie expressed his enthusiasm, stating, "As the life sciences embrace a sophisticated multiomics paradigm, Metabolon is emerging as an industry benchmark and an essential catalyst toward achieving true precision medicine. This investment will enable us to accelerate growth, drive innovation, and further solidify our position as a leader in the metabolomics space."
The financing, led by Trinity Capital, a Phoenix-based specialty lending company, enabled the early retirement of Metabolon's previous $35 million debt facility. This credit facility follows a $25 million equity financing that closed in January 2023, showcasing the company's ability to attract funding even in challenging capital markets environments. Gerry Haines, the Chief Financial Officer at Metabolon, expressed his excitement about the investment of non-dilutive growth capital, emphasizing the company's commitment to advancing scientific research, driving breakthrough discoveries, and developing cutting-edge technology in the metabolomics and bioinformatics space.
Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital, highlighted the company's excitement to partner with Metabolon, recognizing its innovation and excellence in the life sciences sector. By leveraging Metabolon's advanced technology and extensive experience, the team aims to accelerate research and support the company's ongoing growth and expansion in the industry.
Metabolomics, a key focus area for Metabolon, offers a window into health and disease by studying metabolites produced by an organism's biological processes. By measuring thousands of chemical signals forming biological pathways, metabolomics reveals important biomarkers of health and disease, providing insights into drug mechanisms, pharmacodynamics, safety profiles, and individual responses to therapy. Metabolomics plays a crucial role in understanding the combined impact of genetic and non-genetic factors on health, including the effects of drugs, diet, lifestyle, and the microbiome.
Metabolon's scalable, customizable multiomics solutions cater to a wide range of industries, including biopharmaceuticals, population health, consumer products, agriculture, wellness, and academic and government research. With over 10,000 projects for 1,300 clients and inclusion in over 3,000 publications since its founding in 2000, Metabolon continues to drive innovation and excellence in the metabolomics space.
The company's workforce of over 225 employees, with more than 20% holding Ph.D.s, reflects its commitment to scientific excellence and expertise in the field. The recent $60M credit facility marks a significant milestone for Metabolon, positioning it for continued success and leadership in the metabolomics industry.
Led by CEO Rohan (Ro) Hastie, Metabolon stands as a global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research. With over 20 years of experience, 10,000+ projects, 3,000+ publications, and certifications such as ISO 9001:2015, CLIA, and CAP, Metabolon has established itself as a pioneer in the field. The company's Global Discovery Panel, fueled by a vast proprietary metabolomics reference library, offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, to support customer needs from discovery through clinical trials and product life-cycle management.
In a statement regarding the news, CEO Rohan (Ro) Hastie expressed his enthusiasm, stating, "As the life sciences embrace a sophisticated multiomics paradigm, Metabolon is emerging as an industry benchmark and an essential catalyst toward achieving true precision medicine. This investment will enable us to accelerate growth, drive innovation, and further solidify our position as a leader in the metabolomics space."
The financing, led by Trinity Capital, a Phoenix-based specialty lending company, enabled the early retirement of Metabolon's previous $35 million debt facility. This credit facility follows a $25 million equity financing that closed in January 2023, showcasing the company's ability to attract funding even in challenging capital markets environments. Gerry Haines, the Chief Financial Officer at Metabolon, expressed his excitement about the investment of non-dilutive growth capital, emphasizing the company's commitment to advancing scientific research, driving breakthrough discoveries, and developing cutting-edge technology in the metabolomics and bioinformatics space.
Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital, highlighted the company's excitement to partner with Metabolon, recognizing its innovation and excellence in the life sciences sector. By leveraging Metabolon's advanced technology and extensive experience, the team aims to accelerate research and support the company's ongoing growth and expansion in the industry.
Metabolomics, a key focus area for Metabolon, offers a window into health and disease by studying metabolites produced by an organism's biological processes. By measuring thousands of chemical signals forming biological pathways, metabolomics reveals important biomarkers of health and disease, providing insights into drug mechanisms, pharmacodynamics, safety profiles, and individual responses to therapy. Metabolomics plays a crucial role in understanding the combined impact of genetic and non-genetic factors on health, including the effects of drugs, diet, lifestyle, and the microbiome.
Metabolon's scalable, customizable multiomics solutions cater to a wide range of industries, including biopharmaceuticals, population health, consumer products, agriculture, wellness, and academic and government research. With over 10,000 projects for 1,300 clients and inclusion in over 3,000 publications since its founding in 2000, Metabolon continues to drive innovation and excellence in the metabolomics space.
The company's workforce of over 225 employees, with more than 20% holding Ph.D.s, reflects its commitment to scientific excellence and expertise in the field. The recent $60M credit facility marks a significant milestone for Metabolon, positioning it for continued success and leadership in the metabolomics industry.